SCHEMBL1964589

SCHEMBL1964589

CCOC(=O)c1cccc(Nc2ccc(OC)c(OCC)c2)c1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSV O60911 3/20 0.52
CTSL P07711 3/20 0.52
CDC25B P30305 6/20 0.49
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 2/20 0.44
CDC25A P30304 1/20 0.44
CDC25C P30307 1/20 0.44
NPC1 O15118 1/20 0.44
MITF O75030 1/20 0.44
RAB9A P51151 1/20 0.44
PTGS2 P35354 2/20 0.43
TOP1 P11387 1/20 0.43
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1961719 0.95 CTSV (0.55) CTSVCTSLCDC25BMAPTSMN1; SMN2
SCHEMBL1964822 0.91 CTSV (0.58) CTSVCTSLCDC25BMAPTSMN1; SMN2
SCHEMBL1964587 0.87 CTSV (0.50) CTSVCTSLCDC25BMAPTSMN1; SMN2
SCHEMBL1963450 0.85 CTSV (0.44) CTSVCTSLCDC25BMAPTSMN1; SMN2
SCHEMBL1961347 0.82 AKR1C3 (0.57) CTSVCTSLCDC25BMAPTSMN1; SMN2
SCHEMBL1964221 0.82 ALDH1A1 (0.53) CDC25BMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL1961759 0.81 CTSV (0.62) CTSVCTSLCDC25BMAPTSMN1; SMN2
SCHEMBL1962918 0.81 CDC25B (0.59) CDC25BMAPTGAAKMT2ACDC25A
SCHEMBL1964094 0.81 CDC25B (0.55) CDC25BMAPTSMN1; SMN2MEN1GAA
SCHEMBL1963500 0.80 ATM (0.55) CDC25BMAPTKMT2ALMNACDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919892-B1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2013-08-14 EP disclosed
US-8481568-B2 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2013-07-09 US disclosed
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SEPRACOR INC. 2011-06-16 US disclosed
EP-1919892-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2008-05-14 EP disclosed
WO-2007027527-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2007-03-08 WO disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SI, CYP3A5, CYP2D6 CTSV 1759/4885CTSL 1784/4885CDC25B 420/4885
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same SI, CYP3A5, CYP2D6 CTSV 1759/4885CTSL 1784/4885CDC25B 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.